Hear the World - Apply for Funding until January 31

Digital application

The cost of hearing aids

Cost of hearing aids is an issue

Get the latest news of the profession: sign up for our newsletter!

Audiology Worldnews newsletter

Access AWN Special 62nd EUHA Congress (free-access flipbook)

AWN EUHA 2017 special issue

Interested in Audiology-related events?

Audiology Worldnews agenda

TINNET as the next step in tinnitus research: Towards evidence-based medicine

The Tinnitus Research Initiative (TRI) has come a long way to bring tinnitus research from several scientific fields together. The European funded TINNET, 'Better Understanding the Heterogeneity of Tinnitus to Improve and Develop New Treatments', can be regarded as the next step. It aims at coordination and standardization in tinnitus research and the enlargement of an already existing database with results from clinical trials. This should lead to a statistically relevant basis for tinnitus research. It promises the opportunity of standardized processes to enable tailor-made assessment for individual patients.

“At the start of the TRI in 2006 as a private initiative, there was only little tinnitus research compared to the number of people suffering from it. This research was isolated and results remained within the separated domains of ENT, audiology, psychology, psychiatry, and etcetera”, Dr. Berthold Langguth, head of the tinnitus center of Regensburg University concludes. TRI had the vision to bring disciplines together and to share results and insights. “Back then”, Langguth remembers, “the general assumption and conclusion were: 'Tinnitus cannot be cured, so learn to live with it'. The people involved in TRI, however, shared the belief that tinnitus should be treatable in principle – for instance with brain stimulation– although this treatment nor any other treatment was not proven yet. Their motto was and still is: 'Together for a cure'.” Since then, a lot has been achieved. For many patients, the suffering from tinnitus has been reduced.

Evidence base

“But tinnitus still is a very heterogeneous illness. It is difficult to treat”, says Langguth, “treatment is for a large part still mainly pioneering, the domain of pilot studies.” As yet, there are no clearly evidence based treatment methods except cognitive behavioral therapy (CBT) – which comes in several forms. Langguth: “But this doesn't affect the tinnitus percept itself, CBT has the goal to facilitate coping with it. While this provides important relief in many cases, it is not yet the solution for every patient suffering from tinnitus. Apart from that, there are many, many approaches with different rationales. Hearing loss compensation, optionally combined with forms of auditory stimulation, is widely accepted, but large controlled studies demonstrating the efficacy of these approaches are needed. Various innovative forms of individualized auditory stimulation offer sounds or music in frequency areas in the neighborhood of the tinnitus frequency. These forms of individualized auditory stimulation can interact with the neuronal mechanisms that generate tinnitus and have shown promising results in pilot studies.” But there is still a lot unclear, Langguth emphasizes: “How large are the clinical effects? Which variant works best with which type(s) of patients? What can we expect from pharmacological treatment or magnetic and electric brain stimulation? Before these newly developed treatments can be implemented in clinical routine, a conclusive statistical basis from large studies would be needed.”

New knowledge

The TINNET initiative was initiated to change this. It has now been approved by the European Cooperation in Science and Technology (COST) Committee of Senior Officials, thus ensuring European funding. “With that, we get the opportunity to lift tinnitus research to the next level. We still largely depend on the outcomes of isolated trials with a couple of dozens of heterogeneous patients, which causes results to partly depend on group configuration. When data from similar trials from dozens of centers or more can henceforth be introduced in the database, this opens a lot of opportunities.” Once detailed data from many persons is gathered, it will allow us to derive new knowledge, says Langguth: “We could understand in more detail what forms of tinnitus do exist and what the differences between the various forms are. The goal would be to create a data-based expert system, which would provide guidance of which treatment has the best chances for success in a given patient: So hopefully in some years, we can ask the database what would be the recommendation for a 56 years old male, who suffers from a tonal tinnitus since a noise trauma two years ago, and the database would tell us, that a combination of drug X and auditory stimulation Y is the most promising first-line treatment for this individual.”

Dr. Berthold Langguth held a speech on the TINNET initiative during the 8th TRI international Conference from 10-13 March in Auckland, New Zealand. COST invites tinnitus researchers from as many European countries as possible to participate in the project.

Leendert van der Ent

Photo: Lasse Designen - Fotolia
Adding crizotinib to radiation therapy may reduce hearing damage
Adding crizotinib to radiation therapy may reduce hearing damage


© sanjeri - istock.com

Researchers at the Massachusetts General Hospital in Boston recently published the results of a mouse model study showing a new therapeutic combination that may be of interest in patients with neurofibromatosis 2 (NF2) and other patient groups.

A reminder of the commonly used drugs that are potentially ototoxic
A reminder of the commonly used drugs that are potentially ototoxic


© Mukhina1 - istock.com

Pharmacy Times, a full-service pharmacy media resource, recently reported on the main drugs that can cause damage to hearing, and highlighted their mechanisms of action.

Awareness on children and hearing loss in Taiwan
Awareness on children and hearing loss in Taiwan


©Yagi Studio

The Taipei Times recently ran an article on the warning signs that parents need to watch out for that may indicate potential hearing loss in their children.

Graeme Clark and Anders Tjellström 2018 scholarships revealed
Graeme Clark and  Anders Tjellström 2018 scholarships revealed


Cochlear has revealed the winners of the 16th annual Graeme Clark and the seventh annual Anders Tjellström scholarships.

GN Store Nord A/S: annual financial report
GN Store Nord A/S: annual financial report


© baona - istock.com

GN Store Nord A/S recently published its annual financial report showing double-digit growth in revenue and earnings.

Phonak and Advanced Bionics announce MultiBeam Technology
Phonak and Advanced Bionics announce MultiBeam Technology

Speech recognition

© Sonova

Phonak and Advanced Bionics announce today a breakthrough in new microphone technology, that will help people with hearing aids and cochlear implants hear better especially in noisy environments.

Evidence for efficacy of a wearable tinnitus patch
Evidence for efficacy of a wearable tinnitus patch


© AntonioGuillem - istock.com

Researchers working in Sweden at the Sickla ENT-centre in Stockholm and the Citysjukhuset hospital in Gothenburg recently published the results of a double-blind, randomized study of a tinnitus patch called Antinitus carried out in 2016/2017.

Company Directory

New products

Grason-Stadler releases AMTAS FlexGrason-Stadler releases AMTAS Flex

GSI announced the release of AMTAS Flex™, a new tablet-based hearing evaluation tool designed with the busy clinician in mind.  [ ... ]

GN announces GN FalCom for defense and security forcesGN announces GN FalCom for defense and security forces

On January 29, the GN Group presents GN FalCom, a fully-fledged hearing protection solution enabling defense and security forces to hear more, do more and be more.  [ ... ]

ConnectClip newest connectivity device for Oticon Opn™ConnectClip newest connectivity device for Oticon Opn™

Oticon introduces ConnectClip, a state-of-the-art all-in-one wireless Bluetooth microphone and headset for Opn™. [ ... ]